Godavari Biorefineries Secures Japanese Patent for Novel V-ATPase Inhibitor Antiviral Compounds
核心洞察
Godavari Biorefineries (搜索) has secured a Japanese patent for antiviral compounds that inhibit Vacuolar ATPase (搜索) (V-ATPase (搜索)) activity, targeting host-cell mechanisms involved in viral infection pathways.
The patent protects the second medical use of lead compound MSP22 (搜索) and its derivatives, representing a broad-spectrum antiviral strategy that could span multiple viral families.
The company is advancing this research through Sathgen Therapeutics (搜索), its clinical-stage biotechnology arm developing novel cancer and antiviral therapies.
Godavari Biorefineries (搜索) has secured a patent from the Japan Patent Office (JPO) for its invention titled "Use of Compounds for Treating Viral Infections," marking a significant milestone in the company's antiviral drug development program. The patent provides protection for the second medical use of its lead compound MSP22 (搜索) and its derivatives for antiviral applications through inhibition of Vacuolar ATPase (搜索) (V-ATPase (搜索)).
Novel Mechanism Targets Host-Cell Pathways
The patented antiviral compounds work by inhibiting V-ATPase (搜索) activity in cells, a mechanism involved in viral infection pathways. This approach represents a departure from traditional antiviral strategies by targeting host-cell pathways linked to viral infections rather than specific viral components. The compounds may interfere with viral entry and replication processes, potentially offering broader therapeutic applications.
"Research that targets the V-ATPase (搜索) which is a critical cellular enzyme complex exploited by viruses could open new directions in antiviral therapy," said Dr. Sangeeta Srivastava, Executive Director, Godavari Biorefineries (搜索). "This patent reflects our effort to translate scientific research into therapeutic approaches that could eventually address critical global health challenges."
Broad-Spectrum Antiviral Potential
The research suggests these compounds could point toward a broader antiviral strategy spanning multiple viral families, as they act on a host-cell mechanism rather than targeting a specific virus. This mechanism-based approach could potentially address various viral infections through a single therapeutic pathway.
The patent names Dr. Maithili Athavale, Dr. Sandip Gavade, Dr. Prashant Kharkar, and Dr. Sangeeta Srivastava as inventors, recognizing the collaborative scientific effort behind the development of these antiviral compounds.
Strategic Intellectual Property Protection
Securing this patent in Japan represents another step in the company's efforts to protect intellectual property for this antiviral molecule class in key global markets. "Securing this patent in Japan reflects a natural extension of our ongoing work in drug discovery," said Samir Somaiya, Chairman and Managing Director, Godavari Biorefineries (搜索) Limited. "As we progressed with our R&D efforts on lead molecules, we identified their potential to inhibit mechanisms such as V-ATPase (搜索), which are relevant in antiviral applications."
Expanding Life Sciences Portfolio
The invention forms part of Godavari Biorefineries (搜索) Limited's expanding life sciences research program and adds to its growing portfolio in pharmaceutical innovation. The company is advancing its life sciences work through Sathgen Therapeutics (搜索), its clinical-stage biotechnology arm that is developing a pipeline of novel cancer and antiviral therapies.
The program builds on the company's ongoing research into anti-cancer molecules and host-cell biological pathways, areas that have helped inform its expanding antiviral research efforts. Supported by international research collaborations, this initiative reflects the company's commitment to translating scientific discovery into real therapeutic outcomes while strengthening its role in life sciences innovation.